Advertisement

Cellular and Molecular Bioengineering

, Volume 7, Issue 2, pp 172–183 | Cite as

Developing Defined and Scalable 3D Culture Systems for Culturing Human Pluripotent Stem Cells at High Densities

  • Yuguo Lei
  • Daeun Jeong
  • Jifang Xiao
  • David V. SchafferEmail author
Article

Abstract

Human pluripotent stem cells (hPSCs)—including embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs)—are very promising candidates for cell therapies, tissue engineering, high throughput pharmacology screens, and toxicity testing. These applications require large numbers of high quality cells; however, scalable production of human pluripotent stem cells and their derivatives at a high density and under well-defined conditions has been a challenge. We recently reported a simple, efficient, fully defined, scalable, and good manufacturing practice (GMP) compatible 3D culture system based on a thermoreversible hydrogel for hPSC expansion and differentiation. Here, we describe additional design rationale and characterization of this system. For instance, we have determined that culturing hPSCs as a suspension in a liquid medium can exhibit lower volumetric yields due to cell agglomeration and possible shear force-induced cell loss. By contrast, using hydrogels as 3D scaffolds for culturing hPSCs reduces aggregation and may insulate from shear forces. Additionally, hydrogel-based 3D culture systems can support efficient hPSC expansion and differentiation at a high density if compatible with hPSC biology. Finally, there are considerable opportunities for future development to further enhance hydrogel-based 3D culture systems for producing hPSCs and their progeny.

Keywords

Human embryonic stem cells Induced pluripotent stem cells 3D culture system Thermoreversible hydrogel 

Notes

Acknowledgments

This work was supported by California Institute of Regenerative Medicine Grant RT2-02022, a California Institute for Regenerative Medicine training grant T1-00007 fellowship (to Y. L.), and NIH 1R01ES020903-01.

Conflict of interest

Yuguo Lei, Daeun Jeong, Jifang Xiao and David V. Schaffer declare that they have no conflicts of interest.

Ethical standings

All animal studies were carried out in accordance with NIH and University of California, Berkeley guidelines, and approved by the Animal Care and Use Committee of the University of California, Berkeley. No human studies were carried out by the authors for this article.

References

  1. 1.
    Amit, M., I. Laevsky, Y. Miropolsky, K. Shariki, M. Peri, and J. Itskovitz-Eldor. Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nat. Protoc. 6:572–579, 2011.CrossRefGoogle Scholar
  2. 2.
    Badylak, S. F., D. Taylor, and K. Uygun. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu. Rev. Biomed. Eng. 13:27–53, 2011.CrossRefGoogle Scholar
  3. 3.
    Chayosumrit, M., B. Tuch, and K. Sidhu. Biomaterials Alginate microcapsule for propagation and directed differentiation of hESCs to definitive endoderm. Biomaterials 31:505–514, 2010.CrossRefGoogle Scholar
  4. 4.
    Chen, A. K., et al. Critical microcarrier properties affecting the expansion of undifferentiated human embryonic stem cells. Stem Cell Res. 7:97–111, 2011.CrossRefGoogle Scholar
  5. 5.
    Chen, G., et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8:424–429, 2011.CrossRefGoogle Scholar
  6. 6.
    Chen, V. C., et al. Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res. 8:388–402, 2012.CrossRefGoogle Scholar
  7. 7.
    Desbordes, S. C., and L. Studer. Adapting human pluripotent stem cells to high-throughput and high-content screening. Nat. Protoc. 8:111–130, 2012.CrossRefGoogle Scholar
  8. 8.
    Fok, E. Y. L., and P. W. Zandstra. Shear-controlled single-step mouse embryonic stem cell expansion and embryoid body-based differentiation. Stem Cells 23:1333–1342, 2005.CrossRefGoogle Scholar
  9. 9.
    Gafni, O., et al. Derivation of novel human ground state naive pluripotent stem cells. Nature 504:282–286, 2013.CrossRefGoogle Scholar
  10. 10.
    Gerecht, S., J. A. Burdick, L. S. Ferreira, S. A. Townsend, R. Langer, and G. Vunjak-Novakovic. Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc. Natl Acad. Sci. U.S.A. 104:11298–11303, 2007.Google Scholar
  11. 11.
    Hsieh, M. H., and H. T. Nguyen. Molecular mechanism of apoptosis induced by mechanical forces. Int. Rev. Cytol. 245:45–90, 2005.CrossRefGoogle Scholar
  12. 12.
    James, D., A. J. Levine, D. Besser, and A. Hemmati-Brivanlou. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 132:1273–1282, 2005.CrossRefGoogle Scholar
  13. 13.
    Kehoe, D. E., D. Jing, L. T. Lock, and E. S. Tzanakakis. Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. Tissue Eng. Part A 16, 2010.Google Scholar
  14. 14.
    Kriks, S., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551, 2011.Google Scholar
  15. 15.
    Laflamme, M. A., and C. E. Murry. Regenerating the heart. Nat. Biotechnol. 23:845–856, 2005.Google Scholar
  16. 16.
    Lei, Y., S. Gojgini, J. Lam, and T. Segura. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. Biomaterials 32:39–47, 2011.CrossRefGoogle Scholar
  17. 17.
    Lei, Y., and D. V. Schaffer. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc. Natl Acad. Sci. U.S.A. 1–10, 2013.Google Scholar
  18. 18.
    Lindvall, O., Z. Kokaia, and A. Martinez-Serrano. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat. Med. 10:S42–S50, 2004.CrossRefGoogle Scholar
  19. 19.
    McDevitt, T. C., and S. P. Palecek. Innovation in the culture and derivation of pluripotent human stem cells. Curr. Opin. Biotechnol. 19:527–533, 2008.CrossRefGoogle Scholar
  20. 20.
    McNeish, J. Embryonic stem cells in drug discovery. Nat. Rev. Drug Discov. 3:70–80, 2004.CrossRefGoogle Scholar
  21. 21.
    Mohamet, L., M. L. Lea, and C. M. Ward. Abrogation of E-cadherin-mediated cellular aggregation allows proliferation of pluripotent mouse embryonic stem cells in shake flask bioreactors. PLoS One 5:e12921, 2010.CrossRefGoogle Scholar
  22. 22.
    Nie, Y., V. Bergendahl, D. J. Hei, and J. M. Jones. P.S. scalable culture and cryopreservation of human embryonic stem cells on microcarriers. Biotechnol. Prog. 25:20–31, 2009.CrossRefGoogle Scholar
  23. 23.
    Ohgushi, M., and Y. Sasai. Lonely death dance of human pluripotent stem cells: ROCKing between metastable cell states. Trends Cell Biol. 21:274–282, 2011.CrossRefGoogle Scholar
  24. 24.
    Ohgushi, M., et al. Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell 7:225–239, 2010.CrossRefGoogle Scholar
  25. 25.
    Park, I.-H., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:141–146, 2008.CrossRefGoogle Scholar
  26. 26.
    Peerani, R., et al. Niche-mediated control of human embryonic stem cell self-renewal and differentiation. EMBO J. 26:4744–4755, 2007.CrossRefGoogle Scholar
  27. 27.
    Roger, V. L., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2–e220, 2012.CrossRefGoogle Scholar
  28. 28.
    Schulz, T. C., et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One 7:e37004, 2012.CrossRefGoogle Scholar
  29. 29.
    Serra, M., C. Brito, C. Correia, and P. M. Alves. Process engineering of human pluripotent stem cells for clinical application. Trends Biotechnol. 30:350–358, 2012.CrossRefGoogle Scholar
  30. 30.
    Serra, M., et al. Microencapsulation technology: a powerful tool for integrating expansion and cryopreservation of human embryonic stem cells. PLoS One 6:e23212, 2011.CrossRefGoogle Scholar
  31. 31.
    Singh, H., P. Mok, T. Balakrishnan, S. N. B. Rahmat, and R. Zweigerdt. Up-scaling single cell-inoculated suspension culture of human embryonic stem cells. Stem Cell Res. 4:165–179, 2010.CrossRefGoogle Scholar
  32. 32.
    Steiner, D., et al. Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension. Nat. Biotechnol. 28:361–364, 2010.CrossRefGoogle Scholar
  33. 33.
    Stenberg, J., M. Elovsson, R. Strehl, E. Kilmare, J. Hyllner, and A. Lindahl. Sustained embryoid body formation and culture in a non-laborious three dimensional culture system for human embryonic stem cells. Cytotechnology 63:227–237, 2011.CrossRefGoogle Scholar
  34. 34.
    Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872, 2007.CrossRefGoogle Scholar
  35. 35.
    Thomson, J. A. Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147, 1998.Google Scholar
  36. 36.
    Unger, C., H. Skottman, P. Blomberg, M. S. Dilber, and O. Hovatta. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum. Mol. Genet. 17:R48–R53, 2008.CrossRefGoogle Scholar
  37. 37.
    Vallier, L., M. Alexander, and R. A. Pedersen. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J. Cell Sci. 118:4495–509, 2005.Google Scholar
  38. 38.
    Villa-Diaz, L. G., A. M. Ross, J. Lahann, and P. H. Krebsbach. The evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem Cells 31:1–7, 2012.Google Scholar
  39. 39.
    Xu, R.-H., et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 3:196–206, 2008.CrossRefGoogle Scholar
  40. 40.
    Xu, Y., et al. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc. Natl. Acad. Sci. U.S.A. 107:8129–8134, 2010.CrossRefGoogle Scholar
  41. 41.
    Zang, R., D. Li, I. Tang, J. Wang, and S. Yang. Cell-based assays in high-throughput screening for drug discovery. Int. J. Biotechnol. 1:31–51, 2012.Google Scholar
  42. 42.
    Zweigerdt, R., R. Olmer, H. Singh, A. Haverich, and U. Martin. Scalable expansion of human pluripotent stem cells in suspension culture. Nat. Protoc. 6:689–700, 2011.CrossRefGoogle Scholar

Copyright information

© Biomedical Engineering Society 2014

Authors and Affiliations

  • Yuguo Lei
    • 1
    • 2
    • 4
    • 5
  • Daeun Jeong
    • 3
  • Jifang Xiao
    • 2
  • David V. Schaffer
    • 1
    • 2
    • 4
    • 5
    Email author
  1. 1.Department of Chemical and Biomolecular EngineeringUniversity of California, BerkeleyBerkeleyUSA
  2. 2.Department of BioengineeringUniversity of California, BerkeleyBerkeleyUSA
  3. 3.Department of Molecular and Cell BiologyUniversity of California, BerkeleyBerkeleyUSA
  4. 4.California Institute for Quantitative BiosciencesUniversity of California, BerkeleyBerkeleyUSA
  5. 5.Helen Wills Neuroscience InstituteUniversity of California, BerkeleyBerkeleyUSA

Personalised recommendations